Table 4 Clinical and functional outcomes in the 2 groups without and with Stenotrophomonas infection.
From: Stenotrophomonas maltophilia pneumonia in critical COVID-19 patients
 | Statistic | Stenotrophomonas | Test | OR (95% CI) | p value | |
---|---|---|---|---|---|---|
No (103 patients) | Yes (20 patients) | |||||
Mortality | ||||||
 N | N (%) | 62 (60.2%) | 8 (40%) | FFH |  | 0.161 |
 COVID-19-related | N (%) | 37 (35.9%) | 11 (55%) |  |  |  |
 Not COVID-19-related | N (%) | 4 (3.9%) | 1 (5%) |  |  |  |
Length of stay | Me [IQR] | 20 [13–29] | 34 [22–82.5] | MWU |  | 0.000 |
Prone position | N (%) | 53 (52.5%) | 13 (68.4%) | Chi2 | 1.96 (0.69–5.57) | 0.200 |
Thromboembolic event | N (%) | 12 (11.8%) | 3 (15%) | Chi2 | 1.32 (0.34–5.19) | 0.687 |
Hemorrhagic event | N (%) | 12 (11.7%) | 6 (30%) | Chi2 | 3.25 (1.05–10.06) | 0.034 |
Day of Hemorrhagic event | Me [IQR] | 17.5 [10.5–21] | 20 [14–31] | MWU |  | 0.511 |
Intubation | N (%) | 55 (53.4%) | 19 (95%) | Chi2 | 16.6 (2.14–128.5) | 0.001 |
Discharge status | ||||||
 Autonomous | N (%) | 31 (49.2%) | 1 (14.3%) | MWU |  | 0.038 |
 O2 | N (%) | 27 (42.9%) | 4 (57.1%) |  |  |  |
 Ventilation | N (%) | 2 (3.2%) | 0 (0%) |  |  |  |
 Tracheostomy | N (%) | 3 (4.8%) | 2 (28.6%) |  |  |  |
PCFS at discharge | ||||||
 0 | N (%) | 10 (14.7%) | 7 (50%) | MWU |  | 0.242 |
 1 | N (%) | 7 (10.3%) | 0 (0%) |  |  |  |
 2 | N (%) | 19 (27.9%) | 1 (7.1%) |  |  |  |
 3 | N (%) | 14 (20.6%) | 2 (14.3%) |  |  |  |
 4 | N (%) | 18 (26.5%) | 4 (28.6%) |  |  |  |
2-month post-discharge status | ||||||
 Autonomous | N (%) | 47 (81%) | 2 (28.6%) | MWU |  | 0.001 |
 O2 | N (%) | 8 (13.8%) | 2 (28.6%) |  |  |  |
 Ventilation | N (%) | 2 (3.4%) | 1 (14.3%) |  |  |  |
 Tracheostomy | N (%) | 1 (1.7%) | 2 (28.6%) |  |  |  |
PCFS @ 2-Month post discharge | ||||||
 0 | N (%) | 24 (36.9%) | 7 (50%) | MWU |  | 0.710 |
 1 | N (%) | 24 (36.9%) | 1 (7.1%) |  |  |  |
 2 | N (%) | 9 (13.8%) | 1 (7.1%) |  |  |  |
 3 | N (%) | 2 (3.1%) | 0 (0%) |  |  |  |
 4 | N (%) | 6 (9.2%) | 5 (35.7%) |  |  |  |